Tuberculosis Diagnostics Global Market Opportunities And Strategies To 2032

This report describes and explains the tuberculosis diagnostics market and covers 2017-2022, termed the historic period, and 2022-2027 termed the forecast period, along with further forecasts for the period 2027-2032. The report evaluates the market across each region and for the major economies within each region.

The global tuberculosis diagnostics market reached a value of nearly $1,989.7 million in 2022, having increased at a compound annual growth rate (CAGR) of 3.6% since 2017. The market is expected to grow from $1,989.7 million in 2022 to $2,760.6 million in 2027 at a rate of 6.8%. The market is then expected to grow at a CAGR of 7.6% from 2027 and reach $3,976.4 million in 2032.

Growth in the historic period resulted from the rise in the incidence of tuberculosis, increased healthcare expenditure, growth in the number of healthcare facilities and the rise in the adoption of nucleic acid testing. Factors that negatively affected growth in the historic period were COVID-19 impact, the low healthcare access in developing countries and the lack of skilled medical professionals.

Going forward, strong government support, the increasing FDA approvals for tuberculosis diagnostics, the increasing research and development (R&D) activities and the emergence of drug-resistant TB will drive the market. Factors that could hinder the growth of the tuberculosis diagnostics market in the future include the Russia-Ukraine war impact and the stigma and discrimination associated with tuberculosis.

The tuberculosis diagnostics market is segmented by test types into radiographic tests, nucleic acid testing, cytokine detection tests, drug resistance tests, skin test/mantoux test (TST), blood/serology test, smear microscopy tests, cell culture-based tests and other test types. The smear microscopy tests market was the largest segment of the tuberculosis diagnostics market by test types, accounting for $496.9 million or 25.0% of the total market in 2022. The nucleic acid testing market is expected to be the fastest-growing segment going forward at a CAGR of 7.1%.

The tuberculosis diagnostics market is segmented by disease stage into latent tuberculosis and active tuberculosis. The active tuberculosis market was the largest segment of the tuberculosis diagnostics market by disease stage, accounting for $1,415.5 million or 71.1% of the total market in 2022. The latent tuberculosis market is expected to be the fastest-growing segment going forward at a CAGR of 7.2%.

The tuberculosis diagnostics market is segmented by end user into hospitals and diagnostic laboratories, physician’s office laboratories, reference laboratories and academics and research facilities. The hospitals and diagnostic laboratories market was the largest segment of the tuberculosis diagnostics market by end users, accounting for $832.6 million or 41.8% of the total market in 2022. The physician’s office laboratories market is expected to be the fastest-growing segment going forward at a CAGR of 6.9%.

Asia Pacific was the largest region in the tuberculosis diagnostics market, accounting for 39.8% of the global market in 2022. It was followed by North America, Western Europe and the other regions. Going forward, the fastest growing regions in the tuberculosis diagnostics market will be Asia Pacific and North America, where growth will be at CAGRs of 8.1% and 6.7% respectively from 2022-2027.

The global tuberculosis diagnostics market is fragmented, with a large number of small players. The top ten competitors in the market made up to 27.82% of the total market in 2021. Beckton, Dickinson and Company was the largest competitor with 8.48% share of the market, followed by F. Hoffmann-La Roche Ltd with 5.68%, Qiagen N.V. with 5.18%, BioMerieux SA with 3.60%, Danaher Corporation (Cepheid Inc.) with 2.40%, PerkinElmer with 1.12%, Abbott Laboratories Inc. with 0.87%, Thermo Fisher Scientific Inc. with 0.31%, Creative Diagnostics with 0.11%, and Lionex GmbH with 0.07%.

The top opportunities in the tuberculosis diagnostics market by test types will arise in the smear microscopy market, which will gain $193.3 million of global annual sales by 2027. The top opportunities in the tuberculosis diagnostics market by disease stage will arise in the active tuberculosis market, which will gain $533.2 million of global annual sales by 2027. The top opportunities in the tuberculosis diagnostics market by end user will arise in the hospitals and diagnostic laboratories market, which will gain $325.4 million of global annual sales by 2027. The tuberculosis diagnostics market size will gain the most in the USA at $227.5 million.

Market-trend-based strategies for the tuberculosis diagnostics market include focus on next generation sequencing (NGS) platform for TB diagnostics, product innovations, T cell tests for TB infection, artificial intelligence (AI)-based tuberculosis diagnostics, use of portable devices and collaborations between governments and manufacturers.

Player-adopted strategies in the tuberculosis diagnostics industry include enhancing business capabilities through the launch of new products and solutions, offering innovative solutions through securing regulatory approvals and enhancing production capabilities through business expansions.

To take advantage of the opportunities, the publisher recommends the tuberculosis diagnostics companies to increase focus on next generation sequencing (NGS) platform for TB diagnostics, focus on product innovations, focus on artificial intelligence (AI)-based tuberculosis diagnostics, focus on use of portable devices, focus on fast-growing test types, expand in emerging markets, continue to focus on developed markets, focus on partnerships and collaborations, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, continue to focus on fast-growing end-users and target the elderly population.